Ryoncil Is Now Available For Purchase In The United States
Filed with ASX · · 2 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallStory so far
Earlier from Mesoblast
- Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
- Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
- Mesoblast Added to S&P/ASX 200 INDEX
- Arcadium Lithium PLC to be removed from the S&P/ASX 200
- Ryoncil Pricing Set and Available This Quarter
Later from Mesoblast
- First Three Children to Commence Treatment With Ryoncil®
- First Children To Begin Treatment, Medicaid Covers Ryoncil
- Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
- Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs
- Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast